Resource Summary Report

Generated by RRID on Sep 8, 2026

Recombinant Anti-FOXA1 antibody [EPR10881] - ChIP Grade

RRID:AB_3065104
Type: Antibody

Proper Citation

Abcam Cat# ab170933, RRID:AB_3065104

Antibody Information

URL: http://antibodyregistry.org/AB_3065104

Proper Citation: Abcam Cat# ab170933, RRID:AB_3065104

Target Antigen: FOXA1

Host Organism: Rabbit

Clonality: recombinant monoclonal

Comments: Applications: Flow Cyt (Intra), WB, IHC-P, ICC/IF

Antibody Name: Recombinant Anti-FOXA1 antibody [EPR10881] - ChIP Grade

Description: This recombinant monoclonal targets FOXA1

Target Organism: rat, mouse, human

Clone ID: EPR10881

Antibody ID: AB_3065104

Vendor: Abcam

Catalog Number: ab170933

Record Creation Time: 20231110T031034+0000

Record Last Update: 20260829T211728+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-FOXA1 antibody [EPR10881] - ChIP Grade.

No alerts have been found for Recombinant Anti-FOXA1 antibody [EPR10881] - ChIP Grade.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Schwayer C, et al. (2026) Multiscale integration of tissue and chromatin context converts cell heterogeneity into stable intestinal patterning. Cell.

Sasaki Y, et al. (2026) Molecular markers of Rathke's cleft cysts and their clinical correlates: insights from experimental and human analyses. Journal of neurosurgery, 145(1), 103.

Fort G, et al. (2025) Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma. Genes & development, 39(17-18), 1081.

Bokuli?? E, et al. (2025) The expression of transcription factors in the human fetal subthalamic nucleus suggests its origin from the first hypothalamic prosomere. Brain structure & function, 230(2), 33.

Gillis K, et al. (2025) FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma. Developmental cell, 60(3), 472.

Xiao Y, et al. (2025) HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer. Cell metabolism.